Award Notification.pdf
PDF 180 KB Posted
- Attached to
- Preclinical Medications Discovery and Abuse Liability Testing Federal contract opportunity
- Solicitation number
- 75N95021R00048
About this file
This document contains an award notice and related federal contract opportunity notice. The award notice is for contract number 75N95022C00004 awarded to Virginia Commonwealth University on February 22, 2022 for $973,063 to support the National Institute on Drug Abuse Addiction Treatment Discovery Program. The work involves conducting pharmacological evaluations of potential drug addiction treatment medications and preclinical abuse liability studies of new street drugs, medications, or potential medications in rodents. It also provides support for evaluating potential pharmacotherapies for drug use disorders using rodents. The primary emphasis is on testing conducted for NIDA's Addiction Treatment Discovery Program, with secondary focus on generating abuse liability data to inform scheduling of drugs under domestic and international laws. The award was issued by the National Institute on Drug Abuse within the Department of Health and Human Services.
View the file
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
FEDBIZOPS AWARD NOTIFICATION
Solicitation Number:
75N95021R00048
Notice Type:
Award Notice
Contract Award Date:
02/22/2022
Contract Award Number:
75N95022C00004
Contract Award Dollar Amount:
$973,063 ($8,251,228)
Contractor Awarded Name:
Virginia Commonwealth University
Contractor Awarded DUNS:
105300446
Contractor Awarded Address:
PO Box 843039 Virginia Commonwealth University Richmond, VA 23284-3039
Synopsis:
This contract supports the NIDA Addiction Treatment Discovery Program (ATDP), to conduct pharmacological evaluations of potential drug addiction treatment medications and to conduct preclinical abuse liability studies of new street drugs, medications, or potential medications in rodents. It also provides support for evaluation of potential pharmacotherapies for drug use disorders using rodents. The primary emphasis is on testing conducted for NIDA’s ATDP. To a lesser extent, the contract will generate abuse liability data for use in decisions pertaining to scheduling of drugs under domestic laws (Controlled Substances Act) and international treaties (Single Convention and Psychotropic Convention).
Contracting Office Address:
National Institute on Drug Abuse National Institutes of Health c/o 3WFN MSC 6012 301 N Stonestreet Ave Bethesda, Maryland 20892 United States
Primary Point of Contact: Secondary Point of Contact:
Alexander Beraud Tracy Cain Contract Specialist Contracting Officer Alexander.Beraud@nih.gov Tracy.Cain@nih.gov Phone: (301)443-6677 Phone: (301)443-6677 Fax: (301)443-7595 Fax: (301)443-7595
File details come from the government source that posted it. Updated .